Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation.
Clinical trial NCT01217619 · COMPLETED
Trial details
- NCT number
- NCT01217619
- Sponsor
- Baohui Han
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-03-02
- Primary completion
- 2016-06-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.